title: Drugs: An injection of hope.
authors.forename: Duncan
authors.initials: D
authors.lastname: Graham-Rowe
mesh_terms: D000074323:Alemtuzumab; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D017338:Cladribine / Q000009:adverse effects / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003437:Crotonates / Q000009:adverse effects / Q000627:therapeutic use; D000069462:Dimethyl Fumarate; D018450:Disease Progression; D064420:Drug-Related Side Effects and Adverse Reactions; D000068876:Fingolimod Hydrochloride; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D006885:Hydroxybutyrates; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D000069442:Natalizumab; D009570:Nitriles; D011409:Propylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use; D018570:Risk Assessment; D013110:Sphingosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014052:Toluidines / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003437:Crotonates; D005650:Fumarates; D006885:Hydroxybutyrates; D000069442:Natalizumab; D009570:Nitriles; D011409:Propylene Glycols; D015363:Quinolones; D014052:Toluidines; C527525:teriflunomide; D000074323:Alemtuzumab; D017338:Cladribine; C476223:laquinimod; D000069462:Dimethyl Fumarate; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine